Get the Stockscreener App
2.505
1.42%
0.035
Exagen Inc stock is traded at $2.505, with a volume of 7,626.
It is up +1.42% in the last 24 hours and down -16.50% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$2.47
Open:
$2.47
24h Volume:
7,626
Relative Volume:
0.15
Market Cap:
$42.94M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-1.2401
EPS:
-2.02
Net Cash Flow:
$-15.29M
1W Performance:
-3.28%
1M Performance:
-16.50%
6M Performance:
+78.93%
1Y Performance:
+48.22%
1-Day Range:
$2.45
$2.493
1-Week Range:
$2.38
$2.62
52-Week Range:
$1.3003
$3.71
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen to Announce Third Quarter 2024 Results on November 12, 2024 - GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Insider Stock Sales Prove Timely As Market Valuation Descends To US$47m - Simply Wall St
Stonepine Capital Management LLC Has $653,000 Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Inc. (NASDAQ:XGN) Shares Sold by Nantahala Capital Management LLC - Defense World
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com
Exagen Inc. (NASDAQ:XGN) Short Interest Up 20.9% in September - MarketBeat
Octopus Energy acquires solar and storage company Exagen Group - Yahoo Finance
Octopus buys British solar and battery storage firm Exagen - Reuters
PARP Inhibitor Biomarkers Market Expected to Reach $1.75 Billion by 2031 - WhaTech
Autoimmune Disease Diagnostics Market 2024 Global Insights and Business Scenario 2031 - Newstrail
San Diego 2024 Top Tech Awards ceremony set for Sept. 26 at Snapdragon Stadium - CBS News 8
Autoimmune Disease Testing Market to Reach $12.1 Billion, Globally, by 2033 at 8.6% CAGR: Allied Market Research - PR Newswire UK
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now - MSN
Shareholders in Exagen (NASDAQ:XGN) have lost 84%, as stock drops 12% this past week - Yahoo Finance
PARP Inhibitor Biomarkers Market to Surge with 8.8% CAGR by 2031 - WhaTech
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified - Simply Wall St
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference - ForexTV.com
Exagen Inc. (NASDAQ:XGN) Short Interest Down 41.5% in August - MarketBeat
Short Interest in Exagen Inc. (NASDAQ:XGN) Decreases By 41.5% - Defense World
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock - Yahoo Finance
Matthew G. Brown - Wilson Sonsini
Detailed Analysis of Personalized Medicine Market Exploring Future Growth Potential, New Developments, Comp... - WhaTech
XGN (Exagen) EBITDA : $-13.05 Mil (TTM As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Debt-to-EBITDA : -3.02 (As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Net Income From Continuing Operations : $-17.31 Mil (TTM As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Revenue : $56.66 Mil (TTM As of Jun. 2024) - GuruFocus.com
XGN (Exagen) EBITDA per Share : $-0.73 (TTM As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Net-Net Working Capital : $0.09 (As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Earnings Yield % : N/A% (As of Aug. 19, 2024) - GuruFocus.com
Reviewing Exagen (NASDAQ:XGN) and BioNexus Gene Lab (NASDAQ:BGLC) - Defense World
Investing in Exagen Inc (XGN) Is Getting More Attractive - Knox Daily
Personalized Medicine Market to Reach US$ 1,078.17 Billion - GlobeNewswire
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? - MSN
SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations - Business Wire
Hyper Personalized Medicine Market Recovery and Impact Analysis Report – Dako A/S, Exagen Inc., Abbott - TIMC
Exagen stock touches 52-week high at $2.75 amid market fluctuations - Investing.com
Cantor Fitzgerald Research Analysts Lift Earnings Estimates for Exagen Inc. (NASDAQ:XGN) - Defense World
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain - MSN
Q3 2024 EPS Estimates for Exagen Inc. Lifted by Analyst (NASDAQ:XGN) - Defense World
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates - MSN
Exagen Inc (XGN) Q2 2024 Earnings Call Transcript Highlights: Re - GuruFocus.com
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report - Simply Wall St
Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS - Defense World
Exagen Inc. (NASDAQ:XGN) Q2 2024 Earnings Call Transcript - Insider Monkey
Exagen (NASDAQ:XGN) Issues Quarterly Earnings Results - American Banking and Market News
Earnings call: Exagen Inc. reports improved financials, upgrades AVISE CTD - Investing.com
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript - Seeking Alpha
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):